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Abstract Human liver microsomes (HLMs) are used to
simulate human xenobiotic metabolism in vitro. In forensic
and clinical toxicology, HLMs are popularly used to study
the metabolism of new designer drugs for example. In this
work, we present an automated online extraction system we
developed for HLM experiments, which was compared to a
classical offline approach. Furthermore, we present studies
on the metabolism of 11 cathinones; for eight of these, the
metabolism has not previously been reported. Metabolites
were identified based on MS2 and MS3 scans. Fifty-three
substances encompassing various classes of drugs were
employed to compare the established offline and the new
online methods. The metabolism of each of the following 11
cathinones was studied using the new method: 3,4-methy-
lenedioxy-N-benzylcathinone, benzedrone, butylone, dime-
thylcathinone, ethylone, flephedrone, methedrone,
methylone, methylethylcathinone, naphyrone, and pentylone.
The agreement between the offline and the online methods
was good; a total of 158 metabolites were identified. Using
only the offline method, 156 (98.7%) metabolites were iden-
tified, while 151 (95.6%) were identified using only the online
method. The metabolic pathways identified for the 11 cath-
inones included the reduction of the keto group, desalkylation,
hydroxylation, and desmethylenation in cathinones containing
a methylenedioxy moiety. Our method provides a straightfor-
ward approach to identifying metabolites which can then be
added to the library utilized by our clinical toxicological
screening method. The performance of our method compares
well with that of an established offline HLM procedure, but is
as automated as possible.
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Abbreviations
APCI Atmospheric pressure chemical ionization
AU Arbitrary units
bk Beta-keto
CYP Cytochrome P450
EDTA Ethylenediaminetetraacetic acid
ESI Electrospray ionization
GST Glutathione-S-transferase
G6P Glucose-6-phosphate
G6PD Glucose-6-phosphate dehydrogenase
HPLC High-pressure liquid chromatography
HLMs Human liver microsomes
IU International units
LC-MS Liquid chromatography–mass spectrometry
MDPV Methylenedioxypyrovalerone
NADP+ Nicotinic acid adenine dinucleotide phosphate
(oxidized form)
NADPH Nicotinic acid adenine dinucleotide phosphate
(reduced form)
NAT N-Acetyltransferase
Introduction
Identifying metabolites is a necessary task during the drug
development process as well as in the clinical and forensic
toxicological laboratory. Whereas the main focus during
drug development is to determine the presence of a
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metabolite, the main focus in the toxicological laboratory is
to use the metabolites to prove the intake of a particular drug
(e.g., a drug of abuse) when urine samples are analyzed.
Therefore, metabolite generation by in vivo and in vitro sys-
tems is an important tool in both of these fields of application.
Human liver microsomes (HLMs) have become popular
tools for simulating human xenobiotic metabolism in vitro,
mainly because they are easy to use and store. Phase I
metabolism can be studied using HLMs by simply adding
NADPH as a cofactor for the main drug-metabolizing cyto-
chrome P450 enzymes (CYP) [1]. However, there are also
some drawbacks of this approach, such as the absence of
enzymes such as N-acetyltransferase (NAT) or glutathione-
S-transferase (GST). In other words, metabolic pathways
involving those enzymes cannot be studied using HLMs [1].
In the pharmaceutical industry, HLMs are used for me-
tabolite identification and to predict the clearance of drug
candidates in vivo, for example [1]. In the field of forensic
and clinical toxicology, HLMs are popularly employed to
study, for instance, the metabolism of new designer drugs.
The aim of such studies is usually to investigate the metab-
olism of a new designer drug in order to make it detectable
in toxicological screening procedures, or to quantify it using
dedicated methods. Examples include the metabolism of the
synthetic cannabimimetic JWH-018, for which Wintermeyer
et al. [2] used HLMs to study its phase I metabolism in vitro.
Meyer et al. [3] studied the metabolism of methylenedioxy-
pyrovalerone (MDPV) using HLMs (amongst other methods),
and Zaitsu et al. [4] identified several metabolites of butylone
and ethylone. The use of mass spectrometry in studies of the
metabolism of drugs of abuse and doping agents was recently
reviewed, focusing on clinical and forensic toxicology [5].
The process used in HLM experiments can be automated,
and this is an especially common approach in the pharma-
ceutical industry, where a high throughput of experiments is
needed. Several methodologies with fully integrated work-
flows have recently been presented. Drexler et al. [6] devel-
oped a sophisticated automated approach to study the
metabolic stabilities of drug candidates. This approach in-
volved incubation using HLMs, which was carried out in
microplates using an automated liquid handling robot. Similar
approaches were presented by Xu et al. [7] and by Jenkins et
al. [8], which also used a liquid handling robot to carry out the
HLM experiments. Lai et al. [9] described a system where the
autosampler was modified to include a heated agitator and the
samples were subsequently injected into the online extraction
system. The system was used to screen the stability of a
prodrug in development. Kool et al. [10] developed an online
system using rat liver microsomes to study the affinity of
ligands for CYP enzymes.
Regarding the throughput required, assays using, for
example, specialized liquid-handling robots are usually over-
kill for metabolite-generating experiments in the clinical
toxicological laboratory, and the high throughput achievable
is also not needed.
One possible method for achieving a certain degree of
lower-level automation and miniaturization was presented
by Nicoli et al. [11] and Curcio et al. [12], which used a
capillary as the reaction vessel for HLM experiments. This
method included automated metabolite generation, but re-
quired manual sample preparation of the incubation mixture.
The main aim of the work presented in this paper was to
create an automated method with adequate throughput for our
toxicological laboratory to generate phase I metabolites which
could then be added to the library utilized by our clinical
toxicological screening method [13]. Our approach used a
modified, heated autosampler loop for incubation, and the
samples were then transferred onto an online extraction LC-
MS system. After loading the components for the incubation
onto the autosampler, no additional manual steps were needed.
A second aim of this work was to study the metabolism
of 11 different cathinones using HLMs; for eight of these,
the metabolism has not previously been reported, to our
knowledge. Cathinones are a new class of designer drugs
that have appeared in the drugs-of-abuse market in recent
years. They are reported to inhibit plasma membrane mono-
amine transporters, thereby increasing the amount of mono-
amine neurotransmitter in the synaptic cleft [14], which
leads to the pharmacological effects of these drugs.
Materials and methods
Chemicals and reagents
Acetonitrile was purchased from Romil (Cambridge, UK),
acetone from Merck (Darmstadt, Germany), and methanol
and 2-propanol from Seelze (Seelze, Germany); all were of
HPLC gradient grade purity. Purified water was produced in-
house using a central water purification installation (Burkhalter
AG, Worblaufen, Switzerland).
HPLC-grade ammonium acetate and ammonium carbon-
ate were obtained from Scharlau (Taegerig, Switzerland),
while analytical grade formic acid and ammonia were from
Merck. Analytical grade EDTA, potassium dihydrogen
phosphate, potassium hydrogen phosphate, tris base and
glacial acetic acid were obtained from Sigma–Aldrich
(Buchs, Switzerland). Glycerol Ph. Eur. was purchased from
Haenseler (Herisau, Switzerland).
Human liver microsomes (pooled, male and female),
β-nicotinamide adenine dinucleotide phosphate hydrate
(NADP+), D-glucose-6-phosphate dipotassium hydrate
(G6P), and glucose-6-phosphate dehydrogenase (G6PD)
from S. cerevisiae were purchased from Sigma–Aldrich.
Amitriptyline, chlorpromazine, chlorprothixene, duloxe-
tine, ethylone, fenfluramine, fluoxetine, fluphenazine,
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ketamine, methylone, methylphenidate, mianserine, naphyr-
one, oxycodone, and phencyclidine were purchased from
Cerilliant (Round Rock, TX, USA). Bromazepam, butylone,
flephedrone, methaqualone, methylfentanyl, psilocin, tilidine,
and zolpidem were obtained from Lipomed (Arlesheim, Swit-
zerland). Amlodipine, bisacodyl, desipramine, flupentixol,
maprotiline, perphenazine, promazine, propafenone, sertindole,
strychnine, and thioridazine were purchased from Sigma–
Aldrich. Amisulpride, diclofenac, opipramol, pipamperone,
and reboxetine were obtained fromTRC (North York, Canada).
3,4-Methylenedioxy-N-benzylcathinone, benzedrone, dime-
thylcathinone, methedrone, methylethylcathinone, and penty-
lone were purchased from LGC Standards (Wesel, Germany).
Aripiprazol, clotiapine, cinnarizine, cyclizine, dextropropoxy-
phene, doxylamine, fluvoxamine, meclozine, paroxetine, pen-
fluridol, pethidine, pentazocine, remifentanil, sildenafil,
thiethylperazine, thioproperazine, tramadol, and zaleplone
were provided by their respective manufacturers.
LC-MS analysis
The turbulent flow online extraction HPLC system con-
sisted of an HTC PAL autosampler, one Allegro pump for
the online extraction, and one Allegro pump for the
analytical chromatography, all controlled by Aria 1.6.3
software (all from Thermo Fisher Scientific, Basel, Switzer-
land). The autosampler was equipped with a Hamilton
100 μl syringe for CTC autosamplers (Hamilton, Bonaduz,
Switzerland).
The detailed conditions for the online extraction and LC-
MS analysis are described in our previous publications [13,
15]. In brief, samples were extracted online using chroma-
tography based on turbulent flow under alkaline conditions
using ammonium carbonate buffer 10 mM, pH 8.0. A Cy-
clone and a C18 XL column (both from Thermo Fisher
Scientific) were connected in series to achieve sufficient
extraction for substances over a wide polarity range. Ana-
lytical chromatography was performed under acidic condi-
tions on a Betasil phenyl/hexyl column (100×3 mm, 3 μm
particles, Thermo Fisher Scientific) using ammonium ace-
tate 5 mM in water plus 0.1% formic acid and ammonium
acetate 5 mM in methanol plus 0.5% formic acid as mobile
phases. A mixture of acetonitrile/acetone/2-propanol 1/1/1
(v/v/v) was used as a wash phase. The combination of the
two extraction columns and the analytical column could be
connected inline and divided again via two six-port switching
valves controlled by Aria software.
A LXQ linear ion trap mass spectrometer was used for
detection, as controlled by XCalibur 2.0.7 SP1 software
(Thermo Fisher Scientific). Ionization was performed under
atmospheric pressure chemical ionization (APCI) conditions
because of its better performance in terms of ion suppression
susceptibility as compared with electrospray ionization
(ESI). The vaporizer temperature was fixed at 450 °C, the
capillary temperature at 275 °C, the sheath gas flow at 30
arbitrary units (AU), the auxiliary gas flow at 5 AU, and the
discharge current was set to 5 μA. Both positive and nega-
tive ionization were used, with the polarity constantly
switching. Chromatograms were recorded in untargeted
data-dependent acquisition mode. In positive ionization
mode, MS2 spectra were recorded for the four most abundant
ions, and in negative ionization mode they were recorded for
the two most abundant ions. MS3 spectra were recorded for
the most abundant ion from each MS2 spectrum. The thresh-
old for the acquisition of fragment spectra was set to 100
counts per second. The isolation width was set to 1 amu, while
the normalized collision energy for the fragmentation was set
to 35%.
For the online metabolism experiment, the injection loop
was modified to a 200 μl injection loop placed in a column
oven (Thermo Fisher Scientific) that kept the temperature
constant at 37 °C.
Metabolism studies
Identification of metabolites
Metabolites were identified using their MS2 and MS3 mass
spectra. Methods applied were neutral-loss scans and com-
parisons of their fragmentation patterns to the parent sub-
stances. Raw files were examined both manually and
assisted by MassFrontier 7 (Thermo Fisher Scientific).
Solutions
G6P was prepared as a 0.1 M solution in water and NADP+
as a 10 mg/ml solution in water; both were stored as aliquots
at −20 °C until use. The G6PD was dissolved in a mixture
consisting of 20% 40 mM Tris-acetate buffer containing
1 mM EDTA and 80% glycerol to achieve an activity of
103 IU/ml at a protein concentration of 1 mg/ml. Aliquots
were stored at −20 °C until use. The HLM suspensions were
stored as aliquots at −80 °C until usage.
Stock solutions of the test substances were prepared at
1 mg/ml in water or methanol, depending on the solubility
of the substance, and stored at −20 °C until use. Dilutions to
10 mg/l were freshly prepared in phosphate buffer 0.1 M,
pH 7.4. The remaining amount of organic solvent was
always below 1% (v/v).
Offline method
The method was adapted from that of Sohl et al. [16]. To
generate the NADPH needed for the reactions, a NADPH-
generating system was used. It consisted of 50 parts 0.1 M
G6P, 25 parts 10 mg/ml NADP+, and 1 part G6PD at a
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concentration of 1 mg/ml and an activity of 103 IU/ml; all
solutions were prepared as described above. The mixture
was pre-incubated for 1 min before adding it to the incubation
mixture to start the reaction.
Five hundred picomoles of total CYP were used in the
incubation mixture per incubation. The substances were
added diluted in phosphate buffer 0.1 M, pH 7.4 at a
concentration of 10 mg/l. The total volume of the incubation
mixture was 112 μl.
The mixture was incubated in a water bath at 37 °C for 3
h under occasional gently mixing. After 3 h, the reaction
was stopped by adding 110 μl of ice-cold acetonitrile to the
incubation mixture. After vigorous vortexing and centrifu-
gation for 5 min at 11,700×g and 10 °C, the supernatant was
transferred into autosampler vials and stored at 10 °C until
injection. One hundred microliters were analyzed as described
above.
Online method
The same components (NADPH-generating system, HLM
suspension, and substances in phosphate buffer) were used
as described above and used for the offline method. The
autosampler was modified with a 200 μl injection loop
which could be heated to 37 °C using a column oven. The
heated autosampler loop served as the incubation vessel.
The HLM suspension, the NADPH-generating system, and
the phosphate buffer 0.1 M, pH 7.4 containing the substances
at a concentration of 10 mg/l were stored separately in the
cooled autosampler stack at 10 °C until usage.
To combine the incubation mixture, the autosampler was
programmed using the standard options of the Aria software
to first pipette the HLM suspension (15 μl), then the
NADPH-generating system (10 μl), and finally the phosphate
buffer containing the substances (75 μl) into the heated loop.
Afterwards, using the installed 100 μl syringe of the autosam-
pler, the whole incubation mixture was slowly mixed twice by
aspiration followed by immediate ejection. To ensure that the
100 μl incubation mixture was in the heated region of the loop
inside the column oven, a 30 μl air gap was pushed behind the
incubation mixture.
The mixture was incubated in the loop for 50 min, and
then the injection valve was switched to the active position,
which caused the incubation mixture to be transferred onto
the online extraction columns. By transferring the incubation
mixture onto the online extraction columns, the reaction was
stopped by separating the drug-metabolizing enzymes from
the small organic molecules.
Intermediate precision of the online method
To check the stability of the HLM suspension and the
NADPH-generating system in the cooled autosampler stack,
venlafaxine was chosen as a test compound and repeatedly
injected over a 6 h period. Stability was evaluated by calcu-
lating the ratio of the peak area of O-desmethylvenlafaxine to
the peak area of venlafaxine.
To check the between-day intermediate precision of the
method, including different lots of HLM suspensions, clo-
tiapine was injected on four different days. We checked
whether all of the metabolites could be identified on all of
the days.
Method comparison
Fifty-three compounds from various drug classes were me-
tabolized with the offline method as well as the online
method in order to compare the efficiency of metabolite
generation by the new online procedure.
HLM metabolism of 11 cathinones
To study the phase I metabolism of the 11 cathinones (3,4-
methylenedioxy-N-benzylcathinone, benzedrone, butylone,
dimethylcathinone, ethylone, flephedrone, methedrone, meth-
ylone, methylethylcathinone, naphyrone, and pentylone), they
were metabolized with the new online metabolite generation
system, and the resulting chromatograms were analyzed in
order to identify metabolites. The structures of the different
cathinones studied are shown in Fig. 1.
Results
Online method
Using the online method, manual workup was reduced signif-
icantly. The only manual steps needed were the loading of the
HLM suspension, the substances in phosphate buffer, and the
NADPH-generating system onto the autosampler.
During method development, the poor dispensability of
the highly viscous HLM suspension was identified as a
problem. This was solved by setting the drawing speed of
the autosampler syringe to a low value (5 μl/s) and adjusting
the waiting time before the syringe was lifted out of the
autosampler vial from 0.1 s to 1 s in order to allow enough
time for the viscous suspension to flow into the autosampler
syringe.
The remaining volume of HLM suspension that could not
be dispensed was reduced to <5 μl by adjusting the pene-
tration level of the autosampler syringe.
The incubation duration of 50 min was a compromise
between the speed and efficiency of metabolite generation;
both shorter and longer incubation times are possible with
this system. The chromatographic run after the 50 min
incubation took about 33 min. However, a new incubation
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could be started 3 min after the chromatography of the
previous incubation was initiated. When a series of different
drugs were tested, the time needed for single substances
could therefore be reduced to only 50 min (because the
previous incubation was analyzed during the incubation of
the next sample) instead of 83 min, which represents the
sum of the incubation time plus the chromatographic time.
Intermediate precision of the online method
The autosampler stability experiment using the demethylation
of venlafaxine to its main metabolite, O-desmethylvenlafax-
ine, showed that the HLM suspension and the NADPH-
generating system were stable enough to be used over a time
period of at least 6 h when kept in the cooled autosampler
stack at 10 °C; the O-desmethylvenlafaxine to venlafaxine
peak ratio was still 50% of its initial value after 6 h. This is
acceptable considering the goal of the method, which was to
generate metabolites which would then be added to the library
of our toxicological screening method.
In the interday experiment using the metabolites of clo-
tiapine and different lots of HLM suspensions, the same six
metabolites (desmethyl-, MI, MII, MIII, MIV, and MV, as
shown in Table 1) were identified on all four days, demon-
strating that the method achieves reproducible results.
Method comparison
The phase I metabolites of the 53 test compounds identified
with the offline and the online methods are shown in Table 1.
A chromatogram for pipamperone and its metabolites as
well as the corresponding mass spectra of the metabolites
can be seen in Fig. 2.
Using the offline method, a total of 156 metabolites were
identified. Using the online method, a total of 151 metabolites
were identified, among which two metabolites were identified
that were not identified by the offline method, and seven
metabolites identified by the offline method were not identi-
fied using the online method. Therefore, a total of 158 metab-
olites were identified using both methods, among which 156
(98.7%) were identified by the offline method and 151
(95.6%) by the online method. The seven metabolites that
were not identified using the online method were dehydronor-
ketamine, didesmethyltramadol, didesmethyldoxylamine,
didesmethylchlorpromazine, cyclic dinordextropropoxy-
phene, and two oxidation products of thioridazine. The two
metabolites identified solely by the online method were dehy-
drosertindole and an oxidation product of thioproperazine.
Not all of the metabolites could be identified unambigu-
ously using only LC-MS. For example, the differentiation of
N-oxide- and hydroxy metabolites was not always possible
DimethylcathinoneNaphyrone
R1 R2 R3
Benzedrone H CH3
Flephedrone H H F
Methedrone H H OCH3
Methylethcathinone CH3 H CH3
R1 R2
3,4-Methylenedioxy-N-
benzylcathinone
H
Butylone CH3 CH3
Ethylone CH2CH3 H
Methylone CH3 H
Pentylone CH3 CH2CH2CH3
Fig. 1 Structures of the 11 different cathinones studied
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Table 1 Comparison of the offline and online methods. MI, MII, etc. refer to metabolite I, metabolite II, etc. Different chemical structures are
possible for those metabolites based on the acquired MS spectra, as listed in the final column
Substance Metabolites found with
the offline method
Metabolites found
with online method
Comment
Amisulpride Desethyl-, dehydro-,
nitro-, MI
Desethyl-, dehydro-, nitro-, MI MI: hydroxy- or N-oxide
Amitriptyline Desmethylhydroxy-,
desmethyl-, didemethyl-,
MI, MII
Desmethylhydroxy-, desmethyl-,
didemethyl-, MI, MII
MI, MII: hydroxy- or N-oxide
Amlodipine Dehydro- Dehydro-
Aripiprazole Dehydro-, dihydroxy-, MI, MII Dehydro-, dihydroxy-,
MI, MII
MI, MII: hydroxy- or N-oxide
Bisacodyl Didesacetyl- Didesacetyl-
Bromazepam Hydroxy- Hydroxy-
Chlorpromazine Desmethyl-, didesmethyl-,
MI, MII, MIII, MIV
Desmethyl-, MI,
MII, MIII, MIV
MI, MII, MIII, MIV: hydroxy-,
sulfoxide, or N-oxide
Chlorprothixene Desmethyl-, didesmethyl-,
N-oxide, MI, MII
Desmethyl-, didesmethyl-,
N-oxide, MI, MII
MI, MII: hydroxy- or sulfoxide
Cinnarizine MI MI MI: hydroxy- or N-oxide
Clotiapine Desmethyl-, MI, MII,
MIII, MIV, MV
Desmethyl-, MI,
MII, MIII, MIV, MV
MI: demethyl- plus hydroxy-,
N-oxide or sulfoxide, MI and
MIV: hydroxy-, N-oxide or sulfoxide,
MII/MV: dihydroxy-, sulfoxide
plus N-oxide, hydroxy- plus N-oxide,
or hydroxy- plus sulfoxide
Cyclizine Desmethyl- Desmethyl-
Desipramine Desmethyl-, MI, MII, MIII Desmethyl-,
MI, MII, MIII
MI, MII: hydroxy- or N-oxide,
MIII: iminodibenzyl-
Dextropropoxyphene Desmethyl-, MI Desmethyl- MI: cyclic dinor-
Diclofenac Hydroxy- Hydroxy-
Doxylamine Desmethyl-, didesmethyl- Desmethyl-
Duloxetine Hydroxy- Hydroxy-
Fenfluramine Nor- Nor-
Fluoxetine Desmethyl- Desmethyl-
Flupenthixol Nor-, MI, MII Nor-, MI, MII MI: hydroxy-, N-oxide or sulfoxide:
MII: nor- plus hydroxy-, N-oxide or
sulfoxide
Fluphenazine MI, MII MI, MII MI, MII: hydroxy-, N-oxide or sulfoxide
Fluvoxamine Desmethyl-, MI Desmethyl-, MI MI: hydroxy-, N-oxide or sulfoxide
Ketamine Dehydronor-, desmethyl-,
hydroxy-
Desmethyl-, hydroxy-
Maprotiline Desmethyl-, MI, MII, MIII Desmethyl-, MI, MII, MIII MI–MIII: hydroxy-
Meclozine Nor-, MI Nor-, MI MI: hydroxy- or N-oxide
Melitracene Desmethyl- Desmethyl-
Meperidine Desmethyl-, MI, MII Desmethyl-, MI, MII MI: meperidinic acid,
MII: normeperidinic acid
Methaqualone MI, MII, MIII, MIV MI, MII, MIII, MIV MI, MII, MIII, MIV: hydroxy-
Methylfentanyl MI MI MI: hydroxy- or N-oxide
Methylphenidate Ritalinic acid Ritalinic acid
Mianserine Desmethyl-, MI Desmethyl-, MI MI: hydroxy- or N-oxide
Opipramol Nor-, MI, MII, MIII,
MIV, MV, MVI, MVII
Nor, MI, MII, MIII,
MIV, MV, MVI, MVII
MI, MII: hydroxy- or N-oxide;
MIII, MIV, MV, MVI: dihydroxy-
or N-oxide plus hydroxy-
Oxycodone MI, MII MI, MII MI, MII: desmethyl-
Paroxetine Hydroxy- Hydroxy-
Penfluridol Nor-, MI Nor-, MI MI: hydroxy- or N-oxide
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using the acquired MS spectra only. In Table 1, those
metabolites are denoted using the naming scheme of M plus
a Roman numeral, and the different chemical structures are
mentioned in the final column. To elucidate the exact struc-
ture of each metabolite, complementary techniques need to
be applied.
HLM phase I metabolism of 11 cathinones
The proposed structures of the identified phase I metabolites
are shown in Figs. 3, 4, and 5. The general metabolism
pathways seen in several substances include desalkylation
of the amine group (cf. Fig. 1). This metabolite was seen in
all cathinones tested apart from naphyrone, which contains a
tertiary amine included in a 5-ring instead of the secondary
amine present in all of the other tested substances. Other
metabolites observed for more than one substance include
those resulting from the reduction of the keto group and
hydroxylation products. In cathinones containing a methyl-
enedioxy moiety, this moiety can be desmethylenated to the
respective diol, a metabolite which exhibited quite a high
intensity in our experiments. Combinations of the men-
tioned phase I metabolites were also observed for some
substances, indicating subsequent metabolism steps.
Table 1 (continued)
Substance Metabolites found with
the offline method
Metabolites found
with online method
Comment
Pentazocine MI, MII, MIII MI, MII, MIII MI, MII, MIII: hydroxy-
Perphenazine Nor-, MI, MII, MIII Nor-, MI, MII, MIII MI, MII: hydroxy-, N-oxide or
sulfoxide; MIII: nor- plus hydroxy-,
N-oxide or sulfoxide
Phencyclidine MI, MII MI, MII MI, MII: hydroxy- or N-oxide
Pipamperone Dehydro-, dihydro-, MI Dehydro-, dihydro-, MI MI: hydroxy- or N-oxide
Promazine Desmethyl-, MI, MII Desmethyl-, MI, MII MI, MII: hydroxy-, N-oxide or sulfoxide
Propafenone Hydroxy-, Nor- Hydroxy-, Nor-
Psilocine HIAA HIAA HIAA: hydroxyindoleacetic acid
Reboxetine Desethyl-, hydroxy-, MI Desethyl-, hydroxy-, MI MI: oxidation of morpholino ring
Remifentanil MI, MII MI, MII MI: GI-94219; MII: GI-90291
Sertindole Hydroxy- Dehydro-, hydroxy-
Sildenafil Desmethyl-,
MI, MII, MIII
Desmethyl-,
MI, MII, MIII
MI: hydroxy- or N-oxide,
MII: opening of piperazine ring,
MIII: cleavage of piperazine moiety
Strychnine MI, MII, MIII MI, MII, MIII MI, MII: hydroxy- or N-oxide, MIII:
dihydroxy- or hydroxy- plus N-oxide
Thiethylperazine Desmethyl-, MI, MII,
MIII, MIV, MV, MVI,
MVII, MVIII
Desmethyl-, MI, MII,
MIII, MIV, MV,
MVI, MVII, MVIII
MI, MII: hydroxy-, N-oxide or sulfoxide;
MIII, MIV, MV: dihydroxy- or
combinations of N-oxide, sulfoxide
and hydroxy-; MVI: opening of
piperazine ring; MVII, MVIII: desmethyl-
plus hydroxy-, N-oxide or sulfoxide
Thioproperazine Desmethyl-I, desmethyl-II,
didesmethyl-I, didesmethyl-II,
MI, MII, MIII, MIV, MV
Desmethyl-I, desmethyl-II,
didesmethyl-I, didesmethyl-II,
MI, MII, MIII, MIV, MV
MI, MII: hydroxy- or N-oxide or
sulphoxide; MIII: didesmethyl- plus
hydroxy-, N-oxide or sulfoxide; MIV,
MV: desmethyl- plus hydroxy-,
N-oxide or sulfoxide
Thioridazine MI, MII, MIII, MIV, MV,
MVI, MVII, MVIII, MIX
MI, MII, MIII, MIV, MV, MVI;
MIX
MI–MIII: hydroxy-, N-oxide or sulfoxide,
MIV–MVI: dihydroxy- or combinations
of hydroxy-, N-oxide or sulfoxide, MVII,
MVIII: trihydroxy- or combinations
of hydroxy-, N-oxide or sulfoxide
Tilidine Desmethyl-, didesmethyl Desmethyl-, didesmethyl
Tramadol Desmethyl-, desmethyl-II,
didesmethyl-
Desmethyl-, desmethyl-II
Zaleplone Desethyl-, oxo-, oxodesethyl- Desethyl-, oxo-, oxodesethyl-
Zolpidem Hydroxy-I, hydroxy-II, MI Hydroxy-I, hydroxy-II, MI MI: oxidation of methyl group
to carboxylic acid
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Discussion
The majority of the metabolites identified using the offline
method (95.6% of them) could be identified using the online
method. A possible issue for the other seven metabolites that
could not be identified using the online method may be the
difference in incubation times. In the offline method, sub-
stances were incubated for 3 h, but this was reduced to
50 min in the online method to speed up the process.
As sertindole is light sensitive, the lack of identification
of dehydrosertindole by the offline method could be due to
the instability of the parent compound. In the opaque loop
used for online incubation, the incubation mixture was
always protected from the light, which was not the case in
the Eppendorf vials that were used for the offline method.
The online method minimizes the manual preparation
steps required compared to the offline method. This helped
to speed up the whole process and to minimize errors. The
autosampler modifications required were minimal and could
be done in a few minutes. The system can therefore be used
sequentially for clinical toxicological analysis and for me-
tabolism experiments.
In 2005, a method using similar instrumentation was
published. Lai et al. [9] used an automated online extraction
system to study pro-drug stability. The autosampler was mod-
ified and included a heated agitator for sample incubation.
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Fig. 2a–e Chromatogram and
mass spectra for pipamperone
and its metabolites. a
Example of a chromatogram
of pipamperone and its
metabolites. Extracted ion
chromatograms obtained in
positive mode are shown. The
corresponding retention times
(RTs) as well as the mass-to-
charge ratios (m/z) are indicat-
ed. b Mass spectrum of pipam-
perone. c Mass spectrum of
the dehydro metabolite of
pipamperone. d Mass spectrum
of the dihydro metabolite of
pipamperone. e Mass spectrum
of metabolite I (MI) of pipam-
perone. As indicated in Table 1,
the hydroxy metabolite or the
N-oxide metabolite cannot be
distinguished
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Incubation vials containing the biological matrix (e.g., S9
fraction) diluted with buffer were stored in the cooled auto-
sampler stack. The autosampler was programmed to add the
cofactors (e.g., the NADPH-generating system) to this vial
and subsequently transport the whole vial to the heated agita-
tor. After a pre-incubation, the test substance was added. At
programmed time points, the autosampler withdrew an aliquot
for analysis, which was subsequently extracted online using
turbulent flow chromatography. Compared with our method,
the autosampler needed more modifications (e.g., the heated
agitator). In our approach, only the loop needed to be changed
in daily operation. Also, fewer manual steps were needed,
since the autosampler adds not only cofactors and the test
substance to the incubation mixture but also the HLM sus-
pension. However, our method was slower and did not allow
sampling at different time points, since the aim of the method
was a different one. We were not interested in kinetic experi-
ments, only the end points.
Compared to the method of Nicoli et al. [11] and Curcio
et al. [12], where a capillary was used as reaction vessel for
the HLM experiments, our method coupled the use of a
modified injection loop online to an online extraction system.
No manual sample pretreatment was necessary.
Compared to fully integrated and automated solutions, as
presented by Drexler et al. [6], Xu et al. [7], and Jenkins et
al. [8] for instance, our method had a much lower throughput.
The aim of this work was not a fully integrated high-
throughput method but a method that is as automated and
makes it as easy as possible to generate metabolites that can be
added to the library of our toxicological screening method,
and to study the metabolism of new designer drugs.
To our knowledge, among the 11 cathinones studied,
only butylone, ethylone, and methylone have had their
metabolisms published already [4, 17, 18], and these have
always been based on the use of HLMs. For butylone and
ethylone, Zaitsu et al. [4] identified the normetabolite, pro-
duced by the reduction of the keto group to the corresponding
alcohol and demethylenation with subsequent methylation by
the catechol-O-methyltransferase. Meyer et al. [18] were also
able to detect those metabolites for butylone using their stan-
dard toxicological GC-MS screening procedure. In our experi-
ments, we also detected the normetabolites for butylone and
ethylone. Since we did not add the co-substrate needed for the
methylation (S-adenosylmethionine; SAM) to the incubation
mixture, we could not detect the methylated derivatives of
both cathinones, only the demethylenyl-diol-metabolites.
R1 R2 R3 Metabolites identified
Benzedrone H CH3 I, II, V, VI, VII, VIII
Flephedrone H H F I, II
Methedrone H H OCH3 I, III
Methylethcathinone CH3 H CH3 I, II, IV
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Fig. 3 Structures of the proposed metabolites for benzedrone, flephedrone, methedrone, and methylethcathionone
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Interestingly, we did not observe the products of keto-group
reduction, but we were able to identify an additional hydroxy
metabolite for both butylone and ethylone.
The metabolism of methylone was studied by Kamata
et al. [17]. They identified the normetabolite and the
demethylenation products, which were methylated by
the catechol-O-methyltransferase. Meyer et al. [18] identi-
fied an additional metabolite, the demethylenated normetabo-
lite, which was again methylated by the catechol-O-
methyltransferase. We also detected the normetabolite, but
IIIIII
VIV
R1 R2 Metabolites identified
3,4-Methylenedioxy-N-benzylcathinone H I, II, III
HCenolytuB 3 CH3 I, II, IV
HCenolyhtE 2CH3 H I, II, IV
HCenolyhteM 3 H II, III, IV
HCenolytneP 3 CH2CH2CH3 I, II, III, V
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N
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O
O
O
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R1
Fig. 4 Structures of the proposed metabolites for 3,4-methylenedioxy-N-benzylcathinone, butylone, ethylone, methylone, and pentylone
a)
N
O
b)
Fig. 5a–b Structures of the proposed metabolites for a dimethylcathinone, and b naphyrone
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no demethylenation products. Instead, we detected a metabo-
lite due to the reduction of the keto group plus a hydroxy
metabolite.
No information on the metabolism of the other cathinones
could be found in the literature. However, the metabolic path-
ways described for butylone, ethylone, and methylone were
also observed in most other cathinones.
Conclusions
The method presented in this paper provides an easy way to
identify metabolites (which can then be added to the library
of our clinical toxicological screening method) at an ade-
quate throughput. The performance of the method compared
well with that of an established offline HLM procedure, but
it requires less manual work.
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